TransMedics Group, Inc. (NASDAQ:TMDX) Director Sells $1,503,726.25 in Stock

TransMedics Group, Inc. (NASDAQ:TMDX) Director James R. Tobin sold 12,025 shares of the business’s stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $125.05, for a total value of $1,503,726.25. Following the completion of the sale, the director now owns 193,146 shares of the company’s stock, valued at approximately $24,152,907.30. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

TransMedics Group Stock Performance

Shares of NASDAQ:TMDX opened at $127.22 on Thursday. The company has a current ratio of 9.72, a quick ratio of 8.76 and a debt-to-equity ratio of 3.18. The company has a 50-day moving average price of $88.31 and a 200-day moving average price of $78.91. The company has a market cap of $4.19 billion, a price-to-earnings ratio of -374.18 and a beta of 1.87. TransMedics Group, Inc. has a 12 month low of $36.42 and a 12 month high of $132.96.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Tuesday, April 30th. The company reported $0.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.40. TransMedics Group had a positive return on equity of 7.95% and a negative net margin of 3.43%. The company had revenue of $96.90 million for the quarter, compared to the consensus estimate of $83.78 million. During the same quarter in the previous year, the business earned ($0.08) EPS. TransMedics Group’s revenue was up 132.9% compared to the same quarter last year. As a group, equities analysts anticipate that TransMedics Group, Inc. will post 0.62 EPS for the current year.

Analyst Ratings Changes

TMDX has been the topic of several research reports. Canaccord Genuity Group lifted their price target on shares of TransMedics Group from $102.00 to $117.00 and gave the stock a “buy” rating in a research note on Wednesday, May 1st. JPMorgan Chase & Co. lifted their target price on shares of TransMedics Group from $105.00 to $127.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 1st. Morgan Stanley upped their price target on shares of TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 28th. TD Cowen lifted their price objective on TransMedics Group from $100.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. Finally, Oppenheimer boosted their target price on TransMedics Group from $105.00 to $125.00 and gave the company an “outperform” rating in a research note on Wednesday, May 1st. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $119.00.

Hedge Funds Weigh In On TransMedics Group

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Entropy Technologies LP bought a new stake in TransMedics Group in the first quarter valued at $201,000. ProShare Advisors LLC boosted its stake in shares of TransMedics Group by 7.8% during the 1st quarter. ProShare Advisors LLC now owns 5,871 shares of the company’s stock valued at $434,000 after purchasing an additional 427 shares in the last quarter. Russell Investments Group Ltd. increased its position in shares of TransMedics Group by 337,462.5% during the first quarter. Russell Investments Group Ltd. now owns 27,005 shares of the company’s stock valued at $1,997,000 after buying an additional 26,997 shares during the period. Oppenheimer & Co. Inc. raised its stake in TransMedics Group by 156.6% in the first quarter. Oppenheimer & Co. Inc. now owns 26,570 shares of the company’s stock worth $1,965,000 after buying an additional 16,214 shares in the last quarter. Finally, RiverPark Advisors LLC lifted its holdings in TransMedics Group by 361.1% in the first quarter. RiverPark Advisors LLC now owns 6,082 shares of the company’s stock worth $450,000 after buying an additional 4,763 shares during the period. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.